On 24 April, Onxeo announced that the first patient had been treated with AsiDNA, a first-in-class DNA break repair inhibitor, via systemic administration in the Phase I trial. AsiDNA has already generated supportive data from a Phase I trial in melanoma using intratumoural injection. Alongside the Phase I trial Onxeo is conducting a broad preclinical programme that explores AsiDNA in various settings and combinations with other drugs. Two abstracts with preclinical data were presented at the
27 Apr 2018
Onxeo - Phase I with AsiDNA iv starts; first data in H218
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Onxeo - Phase I with AsiDNA iv starts; first data in H218
Valerio Therapeutics (ALVIO:PAR) | 0 0 0.0%
- Published:
27 Apr 2018 -
Author:
Dr Jonas Peciulis -
Pages:
6
On 24 April, Onxeo announced that the first patient had been treated with AsiDNA, a first-in-class DNA break repair inhibitor, via systemic administration in the Phase I trial. AsiDNA has already generated supportive data from a Phase I trial in melanoma using intratumoural injection. Alongside the Phase I trial Onxeo is conducting a broad preclinical programme that explores AsiDNA in various settings and combinations with other drugs. Two abstracts with preclinical data were presented at the